This report was first published by Endpoints News. To see the original version, click here
The second pivotal trial of Compass Pathways’ psilocybin formulation for treatment-resistant depression has succeeded, the company said Tuesday, a result that could help the drug gain approval next year.
The first approval trial of the pill, which is known as COMP360, hit its primary endpoint in June, although by a margin slimmer than Compass had hoped. At that point the company nearly halved in value.
您已阅读11%（494字），剩余89%（3998字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。